Advanced search

The role of erythropoietin in the supportive care of breast cancer

Simon Van Belle (UGent)
(2003) BREAST CANCER RESEARCH AND TREATMENT. 81(Suppl. 1). p.S95-S97
Author
Organization
Abstract
Anemia is a common complication of cancer and cancer therapy, causing numerous physical and psychological distress. The incidence of anemia in breast cancer under cytotoxic therapy depends on the type of chemotherapy, but can be as high as 60% of the patients (defined as < 12 g/dl hemoglobin level). Treatment consists of red blood cell transfusion or epoietin. The impact on quality of life by treating anemia with epoietin, is demonstrated in several randomized trials, even if trials restricted to breast cancer are scarce. On the other hand, the influence of epoietin and correction of anemia by epoietin on treatment outcome is still under investigation. There is some concern about the discovery of erythropoietin-receptors on breast cancer cells, in vitro and in vivo, but until now there is no evidence that epoietin stimulates the growth of these cells.
Keywords
epoietin, quality of life, breast cancer, anemia, TRIAL, PLACEBO, ANEMIA, CHEMOTHERAPY, DOUBLE-BLIND, RECEPTOR EXPRESSION, EPOETIN-ALPHA

Citation

Please use this url to cite or link to this publication:

Chicago
Van Belle, Simon. 2003. “The Role of Erythropoietin in the Supportive Care of Breast Cancer.” Breast Cancer Research and Treatment 81 (Suppl. 1): S95–S97.
APA
Van Belle, Simon. (2003). The role of erythropoietin in the supportive care of breast cancer. BREAST CANCER RESEARCH AND TREATMENT, 81(Suppl. 1), S95–S97. Presented at the Concensus Development Conference on the Medical Treatment of Metastatic Breast Cancer.
Vancouver
1.
Van Belle S. The role of erythropoietin in the supportive care of breast cancer. BREAST CANCER RESEARCH AND TREATMENT. 2003;81(Suppl. 1):S95–S97.
MLA
Van Belle, Simon. “The Role of Erythropoietin in the Supportive Care of Breast Cancer.” BREAST CANCER RESEARCH AND TREATMENT 81.Suppl. 1 (2003): S95–S97. Print.
@article{219298,
  abstract     = {Anemia is a common complication of cancer and cancer therapy, causing numerous physical and psychological distress. The incidence of anemia in breast cancer under cytotoxic therapy depends on the type of chemotherapy, but can be as high as 60% of the patients (defined as < 12 g/dl hemoglobin level). Treatment consists of red blood cell transfusion or epoietin. The impact on quality of life by treating anemia with epoietin, is demonstrated in several randomized trials, even if trials restricted to breast cancer are scarce. On the other hand, the influence of epoietin and correction of anemia by epoietin on treatment outcome is still under investigation. There is some concern about the discovery of erythropoietin-receptors on breast cancer cells, in vitro and in vivo, but until now there is no evidence that epoietin stimulates the growth of these cells.},
  author       = {Van Belle, Simon},
  issn         = {0167-6806},
  journal      = {BREAST CANCER RESEARCH AND TREATMENT},
  keywords     = {epoietin,quality of life,breast cancer,anemia,TRIAL,PLACEBO,ANEMIA,CHEMOTHERAPY,DOUBLE-BLIND,RECEPTOR EXPRESSION,EPOETIN-ALPHA},
  language     = {eng},
  location     = {Vienna, Austria},
  number       = {Suppl. 1},
  pages        = {S95--S97},
  title        = {The role of erythropoietin in the supportive care of breast cancer},
  volume       = {81},
  year         = {2003},
}

Web of Science
Times cited: